BioNTech has passed on Autolus Therapeutics’ dual targeting CAR-T cell therapy. One year after securing a chance to ...
CEO Gina Chapman is also departing the company, which plans to review options for pursuing a reverse merger or other business ...
The Brighterside of News on MSN9d
New CAR-T therapy achieved complete remission in 70% of aggressive cancer patientsCAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia (B-ALL), with ...
Less than 18 months after listing on the Nasdaq, CAR-T therapy developer CARGO Therapeutics has abandoned its development ...
During a parasitic infection, specific immune cells, known as virtual memory T cells, become activated and express a surface molecule called CD22, which prevents an excessive immune reaction.
All Penny Stocks (English) on MSN2d
90% Workforce Reduction Sent This Small Cap SoaringA California-based healthcare company is turning heads mid-week after it announced that it will be cutting its workforce by ...
Detailed price information for Avalon Globocare (ALBT-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback